It couldnâ€™t possibly. " Drug makers would be especially unlikely to turn away from immunotherapy, where the promising science has set off a "gold rush mentality," according to Mark Edwards of Bioscience Advisors, a company which tracks pharmaceutical licensing deals. The National Institutes of Health, the parent agency of the National Cancer Institute, currently has about 400 cooperative research agreements with companies, and licenses hundreds of patented inventions for   development. 